Durect (DRRX) drops 46.6% AH after stating Phase III trial results for its Posidur...

|About: Durect Corporation (DRRX)|By:, SA News Editor

Durect (DRRX) drops 46.6% AH after stating Phase III trial results for its Posidur post-operative pain-relief drug "did not reach statistical significance." The company says it will now "hold a pre-NDA meeting with the FDA" to discuss the results. (previously)